Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

The success surrounding the medications for obesity and diabetes has sparked research into whether they could also be an ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, into Phase III trials for treating MASH ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.